Iovance Biotherapeutics Stock Performance
| IOVA Stock | USD 3.63 0.09 2.54% |
The company retains a Market Volatility (i.e., Beta) of 0.71, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Iovance Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Iovance Biotherapeutics is expected to be smaller as well. At this point, Iovance Biotherapeutics has a negative expected return of -1.15%. Please make sure to check out Iovance Biotherapeutics' kurtosis, as well as the relationship between the day median price and relative strength index , to decide if Iovance Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Iovance Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.54 | Five Day Return 2.54 | Year To Date Return (53.40) | Ten Year Return (67.18) | All Time Return (96.70) |
Last Split Factor 1:100 | Last Split Date 2013-09-26 |
1 | Acquisition by Vogt Frederick G of 20835 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 01/24/2025 |
2 | Acquisition by Vogt Frederick G of 10417 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 01/27/2025 |
3 | Whats Wrong With Iovance Biotherapeutics Stock | 01/30/2025 |
4 | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 | 02/21/2025 |
5 | Q4 2024 Iovance Biotherapeutics Inc Earnings Call Transcript | 02/28/2025 |
6 | Disposition of 07 shares by Graf Finckenstein Friedrich of Iovance Biotherapeutics subject to Rule 16b-3 | 03/03/2025 |
7 | Acquisition by Igor Bilinsky of 3516 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 03/04/2025 |
8 | Acquisition by Bellemin Jean-marc of 93750 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 03/05/2025 |
9 | Iovance Biotherapeutics Price Target Cut to 30.00 by Analysts at Chardan Capital | 03/06/2025 |
10 | Acquisition by Puri Raj K. of 117190 shares of Iovance Biotherapeutics subject to Rule 16b-3 | 03/07/2025 |
11 | Down Nearly 80 percent From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up | 03/12/2025 |
12 | Disposition of 8334 shares by Puri Raj K. of Iovance Biotherapeutics subject to Rule 16b-3 | 03/14/2025 |
13 | Is Iovance Biotherapeutics, Inc. the Most Oversold Penny Stocks to Buy According to Analysts | 03/17/2025 |
| Begin Period Cash Flow | 181.3 M |
Iovance |
Iovance Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 760.00 in Iovance Biotherapeutics on December 25, 2024 and sell it today you would lose (397.00) from holding Iovance Biotherapeutics or give up 52.24% of portfolio value over 90 days. Iovance Biotherapeutics is currently does not generate positive expected returns and assumes 4.291% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Iovance, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Iovance Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Iovance Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Iovance Biotherapeutics, and traders can use it to determine the average amount a Iovance Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2676
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IOVA |
Estimated Market Risk
| 4.29 actual daily | 38 62% of assets are more volatile |
Expected Return
| -1.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.27 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Iovance Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Iovance Biotherapeutics by adding Iovance Biotherapeutics to a well-diversified portfolio.
Iovance Biotherapeutics Fundamentals Growth
Iovance Stock prices reflect investors' perceptions of the future prospects and financial health of Iovance Biotherapeutics, and Iovance Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Iovance Stock performance.
| Return On Equity | -0.57 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (1.17) % | ||||
| Current Valuation | 893.53 M | ||||
| Shares Outstanding | 327.88 M | ||||
| Price To Earning | (3.51) X | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 7.07 X | ||||
| Revenue | 164.07 M | ||||
| Gross Profit | 40.08 M | ||||
| EBITDA | (395.28 M) | ||||
| Net Income | (372.18 M) | ||||
| Cash And Equivalents | 424.46 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 57.26 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.72 X | ||||
| Book Value Per Share | 2.33 X | ||||
| Cash Flow From Operations | (352.98 M) | ||||
| Earnings Per Share | (1.28) X | ||||
| Market Capitalization | 1.16 B | ||||
| Total Asset | 910.43 M | ||||
| Retained Earnings | (2.38 B) | ||||
| Working Capital | 334.68 M | ||||
| Current Asset | 290.82 M | ||||
| Current Liabilities | 10.12 M | ||||
About Iovance Biotherapeutics Performance
By analyzing Iovance Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Iovance Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Iovance Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Iovance Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 151.66 | 277.01 | |
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.52) | (0.55) |
Things to note about Iovance Biotherapeutics performance evaluation
Checking the ongoing alerts about Iovance Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Iovance Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Iovance Biotherapeutics generated a negative expected return over the last 90 days | |
| Iovance Biotherapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 164.07 M. Net Loss for the year was (372.18 M) with profit before overhead, payroll, taxes, and interest of 40.08 M. | |
| Iovance Biotherapeutics currently holds about 424.46 M in cash with (352.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Iovance Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 |
- Analyzing Iovance Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Iovance Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Iovance Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Iovance Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Iovance Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Iovance Biotherapeutics' stock. These opinions can provide insight into Iovance Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Iovance Stock analysis
When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |